MAP2K7 and melanoma: Some clinical trials reported that melanoma patients, carried BRAFV600R, achieved favorable outcomes after receiving BRAF/MEK inhibitors,[29,30] indicating the potential better therapeutic responses of PTC patients carried the novel variant of BRAF after treated with BRAF/MEK inhibitors.